ANBL1531, A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or AlK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
Contact:
NCT Number:
Protocol:
AAAS0652
Study Status:
Active/Enrolling
Population:
Pediatrics/Adult
Phase:
III
This randomized clinical trial is examining whether the addition of radio- labelled MIBG or Crizotinib will improve the survival of high risk Neuroblastoma patients, as compared to standard treatment. Patients will be non-randomly assigned to Crizotinib based on tumor testing. All other patients will be randomized to receive standard therapy or standard therapy + MIBG.
Are you Eligible? (Inclusion Criteria)
- Between 1 and 30 years of age
- Have a diagnosis of High Risk Neuroblastoma
- Enrolled on ANBL00B1
- Patients must also meet all other eligibility criteria as outlined in the study
Specialty Area(s)
Childhood and Adolescent Cancers (Pediatric)
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032